Michael Skynner

Mike Skynner, Ph.D., is vice president of operations at Bicycle Therapeutics.He joined Bicycle Therapeutics from Pfizer where he led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium (RDC). The RDC was an innovative agreement between Pfizer and 20 leading U.K. universities that created research partnerships between Pfizer, academic researchers and patient groups to develop new therapies for rare and orphan diseases using a new collaborative paradigm. As part of those activities he also established Pfizer’s Genetic Medicine Institute, a bespoke research unit in central London embedded within the U.K. gene therapy academic community. Previously, he established a discovery performance unit at GlaxoSmithKline (GSK) focused on developing therapeutics targeting inflammatory kinases using an externalised and partnered model with leading European biotechnology companies. In his time at GSK he successfully advanced multiple molecules from screening into clinical trials. Prior to GSK he co-founded a successful biotech start-up company, Cambridge Biotechnology Ltd., (CBT), which specialised in developing small molecule and peptide therapeutics for inflammation and metabolic disease. CBT was sold to Swedish Orphan Biovitrum.

Mike obtained his Ph.D. in biochemistry at Imperial College and is an author on over 30 peer-reviewed scientific publications.

Michael Skynner is the Chief Operating Officer at Bicycle Therapeutics, based in Europe. With a background in Biotechnology, Michael Skynner has a rich history of leadership and innovation.Michael Skynner studied Ph.D Biochemistry at Imperial College London. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.